Treat and extend versus pro re nata regimens of ranibizumab and aflibercept in neovascular age-related macular degeneration: a comparative study
Sign Up to like & getrecommendations! Published in 2019 at "Graefe's Archive for Clinical and Experimental Ophthalmology"
DOI: 10.1007/s00417-019-04404-0
Abstract: To compare treatment efficacy of anti-VEGF medications following pro re nata (PRN, “as needed”, monthly injections only in case of active disease) or treat and extend (T&E, progressive extension of treatment intervals up to 12… read more here.
Keywords: treatment; group; ranibizumab aflibercept; prn ... See more keywords
Dispensing Patterns of Ranibizumab and Aflibercept for the Treatment of Neovascular Age-Related Macular Degeneration: A Retrospective Cohort Study in Australia
Sign Up to like & getrecommendations! Published in 2017 at "Advances in Therapy"
DOI: 10.1007/s12325-017-0624-6
Abstract: IntroductionAnti-vascular endothelial growth factor therapy is the standard of care for neovascular age-related macular degeneration (nAMD). The dosage of two licensed agents, ranibizumab and aflibercept, was established through clinical trials; however, it is unclear if… read more here.
Keywords: difference; treatment; mean difference; ranibizumab aflibercept ... See more keywords
Real-World Results of Switching Treatment from Ranibizumab to Aflibercept in Macular Oedema Secondary to Branch Retinal Vein Occlusion
Sign Up to like & getrecommendations! Published in 2018 at "Ophthalmology and Therapy"
DOI: 10.1007/s40123-018-0149-3
Abstract: IntroductionTo investigate treatment outcomes after switching from ranibizumab to aflibercept intravitreal injections in patients with macular oedema (MO) secondary to branch retinal vein occlusion (BRVO).MethodsEligible patients with refractory MO secondary to BRVO, post treatment with… read more here.
Keywords: oedema secondary; branch retinal; treatment; macular oedema ... See more keywords
Real-world visual acuity outcomes between ranibizumab and aflibercept in treatment of neovascular AMD in a large US data set
Sign Up to like & getrecommendations! Published in 2017 at "Eye"
DOI: 10.1038/eye.2017.143
Abstract: PurposeTo examine 12-month real-world visual acuity outcomes and treatment patterns in neovascular age-related macular degeneration (nAMD) eyes, including those with pigment epithelial detachment (PED), receiving ranibizumab or aflibercept.Patients and methodsElectronic medical records were used to… read more here.
Keywords: real world; aflibercept treatment; ranibizumab; ranibizumab aflibercept ... See more keywords
Impact of intravitreal ranibizumab, aflibercept and bevacizumab on retinal ganglion cell and nerve fibre layer thickness in Neovascular age‐related macular degeneration
Sign Up to like & getrecommendations! Published in 2022 at "Acta Ophthalmologica"
DOI: 10.1111/aos.15283
Abstract: To compare the effects of monotherapy with intravitreal ranibizumab, aflibercept and bevacizumab on retinal ganglion cell layer (RGCL) and retinal nerve fibre layer (RNFL) in patients with naïve neovascular age‐related macular degeneration (nAMD). read more here.
Keywords: intravitreal ranibizumab; bevacizumab retinal; layer; aflibercept bevacizumab ... See more keywords
Comparison of pain during intravitreal dexamethasone, ranibizumab and aflibercept injection
Sign Up to like & getrecommendations! Published in 2019 at "Clinical and Experimental Optometry"
DOI: 10.1111/cxo.12974
Abstract: Background This study aimed to compare pain scores of patients during intravitreal aflibercept, ranibizumab or dexamethasone implant injection procedures. Methods This study included 162 eyes of 162 patients, who received intravitreal ranibizumab, aflibercept or dexamethasone… read more here.
Keywords: dexamethasone implant; injection; ranibizumab aflibercept; pain ... See more keywords
Factors influencing macular atrophy growth rates in neovascular age-related macular degeneration treated with ranibizumab or aflibercept according to an observe-and-plan regimen
Sign Up to like & getrecommendations! Published in 2018 at "British Journal of Ophthalmology"
DOI: 10.1136/bjophthalmol-2018-312430
Abstract: Background/aims To investigate the factors associated with macular atrophy (MA) growth rates in neovascular age-related macular degeneration treated with either ranibizumab or aflibercept. Methods We obtained data from two identical prospective studies using ranibizumab or… read more here.
Keywords: growth rates; age; macular atrophy; ranibizumab aflibercept ... See more keywords
Comparison of intravitreal ranibizumab, aflibercept and bevacizumab therapies in diabetic macular edema with serous retinal detachment
Sign Up to like & getrecommendations! Published in 2022 at "European Journal of Ophthalmology"
DOI: 10.1177/11206721221144797
Abstract: Purpose To compare the effects of ranibizumab, aflibercept and bevacizumab treatments in treatment-naive diabetic macular edema(DME) patients with serous retinal detachment(SRD). Material and methods This is a retrospective, comparative study. In a sample of 86… read more here.
Keywords: serous retinal; retinal detachment; macular edema; aflibercept bevacizumab ... See more keywords
The cost-effectiveness of bevacizumab, ranibizumab and aflibercept for the treatment of age-related macular degeneration—A cost-effectiveness analysis from a societal perspective
Sign Up to like & getrecommendations! Published in 2018 at "PLoS ONE"
DOI: 10.1371/journal.pone.0197670
Abstract: Background The discussion on the use of bevacizumab is still ongoing and often doctors are deterred from using bevacizumab due to legal or political issues. Bevacizumab is an effective, safe and inexpensive treatment option for… read more here.
Keywords: bevacizumab; treatment; cost; ranibizumab aflibercept ... See more keywords
Real Life Multicenter Comparison of 24-Month Outcomes of Anti-VEGF Therapy in Diabetic Macular Edema in Turkey: Ranibizumab vs. Aflibercept vs. Ranibizumab-Aflibercept Switch
Sign Up to like & getrecommendations! Published in 2023 at "Medicina"
DOI: 10.3390/medicina59020263
Abstract: The aim of this study was to compare the outcomes of diabetic macular edema (DME) treated with aflibercept (AFB) or ranibizumab (RNB) only, and after switching from RNB to AFB. This was a retrospective, real-world,… read more here.
Keywords: month; rnb afb; ranibizumab aflibercept; rnb ... See more keywords